ST. LOUIS, – WUGEN Inc., a biotechnology company developing a novel universal allogeneic CAR-T therapy platform, today announced that it has entered into an exclusive license agreement with Washington University in St. Louis for intellectual property and technology related to CAR-T therapies. The agreement gives WUGEN exclusive rights to technology from the laboratory of noted bone marrow specialist and oncologist John F. DiPersio, M.D., Ph.D., and will be used in the development of novel CAR-T approaches for blood cancer therapies.
“This collaboration with WUGEN is key to facilitating breakthroughs in CAR-T medicine as we explore how allogeneic CAR-T technology can address an unmet medical need in T-cell malignancies,” said Dr. DiPersio, Chief of the Division of Oncology at Washington University School of Medicine in St. Louis. “We hope that developing an effective “off-the-shelf” allogeneic CAR-T cell therapy will overcome challenges associated with fratricide and graft versus host disease.”
WUGEN Inc. is a biotechnology company developing a novel CAR-T therapy platform including an “off-the-shelf” fratricide-resistant CAR-T cell therapy for T-cell malignancies. WUGEN’s state-of-the-art gene editing technologies and cutting-edge CAR-T cell therapy address some of the challenges that have limited the clinical development of allogeneic CAR-T cells. WUGEN was founded based on technology licensed from Washington University in St. Louis. For more information please visit www.wugen.com.
For media inquiries contact:
David Schull or Travis Kruse
SOURCE WUGEN Inc.